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ABSTRACT 
Glucocorticoids (GCs) are steroid hormones that have a major impact on human metabolism 
and are essential for life. Chronic GC overexposure, called Cushing’s syndrome, is 
characterized by central obesity, muscle atrophy, osteoporosis, hypertension, impaired 
glucose tolerance and neurocognitive impairment. Cushing’s syndrome can be caused by 
increased endogenous GC production or arise due to pharmacological GC treatment.  
 
This thesis is based on four studies, including four different patient populations, aimed at 
investigating outcomes in patients with Cushing’s syndrome and patients receiving current 
standard GC replacement therapy for adrenal insufficiency. In a large study of patients with 
hypopituitarism it was demonstrated that GC replacement therapy was independently 
associated with reduced bone mineral density in women with adrenal insufficiency receiving 
an average daily hydrocortisone dose of approximately 20 mg. In another study of adult 
patients, treated for Cushing’s disease during childhood, final adult height was compromised 
in the majority of the patients and the prevalence of hypertension was high. In a study of 
patients in long-term remission after successful treatment for Cushing’s syndrome, numerous 
domains of cognitive function were impaired at long-term follow-up in comparison to healthy 
individuals. Finally it was demonstrated that short-term treatment with growth hormone and 
testosterone increases skeletal muscle mass in men on chronic low dose GC treatment.  
 
In conclusion, this thesis demonstrates that long-term GC exposure has various long-term 
adverse health related consequences for patients receiving GC replacement therapy and in 
patients in long-term remission from Cushing’s syndrome. Furthermore, anabolic treatment 
with growth hormone and testosterone has the potential to improve GC induced muscle 
wasting. 
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